Cann Group (ASX:CAN) Is Making Moderate Use Of Debt
May 18
Australian (ASX) Pharma Industry Analysis
UpdatedJun 01, 2023
DataAggregated Company Financials
Companies36
- 7D0.5%
- 3M12.4%
- 1Y-3.6%
- YTD1.7%
Over the last 7 days, the Pharma industry has dropped 2.6%, driven by a pullback from Neuren Pharmaceuticals of 4.7%. Meanwhile, Clarity Pharmaceuticals actually outperformed within the industry, gaining 11% in the last week. However, the industry is down 5.0% over the past year. As for the next few years, earnings are expected to grow by 31% per annum.
Industry Valuation and Performance
Has the Australian Pharma Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Thu, 01 Jun 2023 | AU$4.1b | AU$993.2m | -AU$640,306,659.00 | 18.8x | -6.3x | 4.1x |
| Sat, 29 Apr 2023 | AU$4.3b | AU$993.2m | -AU$641,969,868.00 | 20.5x | -6.7x | 4.3x |
| Mon, 27 Mar 2023 | AU$4.0b | AU$995.9m | -AU$648,651,745.00 | 18.2x | -6.2x | 4.1x |
| Wed, 22 Feb 2023 | AU$3.6b | AU$981.5m | -AU$594,318,566.00 | 16.6x | -6x | 3.6x |
| Fri, 20 Jan 2023 | AU$3.7b | AU$948.3m | -AU$544,428,006.00 | 13x | -6.9x | 3.9x |
| Sun, 18 Dec 2022 | AU$3.9b | AU$948.3m | -AU$544,428,006.00 | 13.3x | -7.1x | 4.1x |
| Tue, 15 Nov 2022 | AU$4.3b | AU$948.3m | -AU$544,428,005.00 | 13.2x | -7.9x | 4.5x |
| Thu, 13 Oct 2022 | AU$4.2b | AU$882.1m | -AU$556,645,005.00 | 12.2x | -7.5x | 4.7x |
| Sat, 10 Sep 2022 | AU$4.2b | AU$943.4m | -AU$537,548,829.00 | 12.7x | -7.8x | 4.4x |
| Mon, 08 Aug 2022 | AU$3.9b | AU$819.9m | -AU$339,669,589.00 | 15.6x | -11.6x | 4.8x |
| Wed, 06 Jul 2022 | AU$3.4b | AU$818.2m | -AU$353,932,589.00 | 13.2x | -9.5x | 4.1x |
| Fri, 03 Jun 2022 | AU$3.9b | AU$818.2m | -AU$353,932,589.00 | 14.8x | -11.1x | 4.8x |
| Sun, 01 May 2022 | AU$4.1b | AU$800.9m | -AU$348,637,558.00 | 15.7x | -11.7x | 5.1x |
| Tue, 29 Mar 2022 | AU$4.2b | AU$799.2m | -AU$341,805,125.00 | 18.1x | -12.4x | 5.3x |
| Thu, 24 Feb 2022 | AU$4.4b | AU$743.6m | -AU$460,156,833.00 | 19.9x | -9.6x | 5.9x |
| Sat, 22 Jan 2022 | AU$4.8b | AU$758.4m | -AU$450,516,414.00 | 20.6x | -10.6x | 6.3x |
| Mon, 20 Dec 2021 | AU$4.8b | AU$758.4m | -AU$450,516,414.00 | 23.7x | -10.5x | 6.3x |
| Wed, 17 Nov 2021 | AU$4.9b | AU$758.4m | -AU$447,307,205.00 | 24.1x | -11x | 6.5x |
| Fri, 15 Oct 2021 | AU$4.7b | AU$753.7m | -AU$446,965,453.00 | 23.5x | -10.6x | 6.3x |
| Sun, 12 Sep 2021 | AU$4.8b | AU$753.9m | -AU$445,060,581.00 | 21.9x | -10.7x | 6.3x |
| Tue, 10 Aug 2021 | AU$4.1b | AU$752.8m | -AU$442,004,016.00 | 21.3x | -9.3x | 5.4x |
| Mon, 03 May 2021 | AU$4.8b | AU$758.7m | -AU$449,177,839.00 | 12.3x | -10.6x | 6.3x |
| Thu, 04 Feb 2021 | AU$4.5b | AU$759.6m | -AU$478,696,362.00 | 75.2x | -9.5x | 6x |
| Sun, 08 Nov 2020 | AU$3.7b | AU$761.5m | -AU$402,127,165.00 | 21.2x | -9.2x | 4.9x |
| Sat, 01 Aug 2020 | AU$3.7b | AU$773.8m | -AU$314,501,632.00 | 40.2x | -11.9x | 4.8x |
Price to Earnings Ratio
-10x
Current Industry PE
- Investors are pessimistic on the Australian Pharmaceuticals industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The 3-year average PS ratio of 5.2x is higher than the industry's current PS ratio of 4.1x.
Past Earnings Growth
- The earnings for companies in the Pharmaceuticals industry have deteriorated over the last three years.
- Meanwhile revenues for these companies have grown 9.0% per year.
- This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has caused losses to expand.
Industry Comparison
How does Australian Pharma compare with similar industries?
| AU Market | -1.60% | |
| Healthcare | 0.068% | |
| Pharma | 0.55% | |
| Pharma | 0.55% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| NEU Neuren Pharmaceuticals | AU$14.15 | 2.5% +AU$44.3m | 269.5% | PE9733.2x | |
| VIT Vitura Health | AU$0.34 | 9.5% +AU$16.7m | 32.7% | PE18.6x | |
| ZLD Zelira Therapeutics | AU$2.30 | 155.6% +AU$15.9m | 94.9% | PS29.3x | |
| MYX Mayne Pharma Group | AU$3.77 | 5.3% +AU$15.5m | -37.2% | PS0.9x | |
| MVP Medical Developments International | AU$0.82 | 13.0% +AU$8.2m | -67.4% | PS1.6x |
